ENDRA Life Sciences (NASDAQ: NDRA): Medical Diagnostic Play in the $100B+MASH+GLP Healthcare Boom
While investors chase the obvious opportunity in the emerging MASH drug market, another potentially powerful theme is developing just beneath the surface. Diagnostics. If metabolic dysfunction–associated steatohepatitis becomes a widely…
